Tempus AI (TEM) and Recursion Pharmaceuticals (RXRX) extended their data license agreement through November 2029 and revised the contract's fee structure.
Up to $84 million in discretionary payments over the next two years will be replaced with $42 million in committed payments over three years, Tempus said Monday in a statement.
Tempus said it also signed a separate agreement granting the company a nonexclusive, worldwide license to Recursion's proprietary RNA sequencing model.
Tempus shares rose 1.8% in Monday trading, and Recursion climbed 2.6%.
Price: 79.27, Change: +1.43, Percent Change: +1.83
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments